View Future GrowthSoulbrain 過去の業績過去 基準チェック /16Soulbrainの収益は年間平均-13.1%の割合で減少していますが、 Chemicals業界の収益は年間 増加しています。収益は年間1.1% 5%割合で 減少しています。 Soulbrainの自己資本利益率は7.6%であり、純利益率は8.6%です。主要情報-13.05%収益成長率-12.92%EPS成長率Chemicals 業界の成長13.95%収益成長率-5.03%株主資本利益率7.56%ネット・マージン8.56%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • Mar 21Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: ₩10,285 (down from ₩15,296 in FY 2024). Revenue: ₩923.4b (up 7.0% from FY 2024). Net income: ₩79.1b (down 33% from FY 2024). Profit margin: 8.6% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 22%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.分析記事 • Mar 24There May Be Some Bright Spots In Soulbrain's (KOSDAQ:357780) EarningsSoft earnings didn't appear to concern Soulbrain Co., Ltd.'s ( KOSDAQ:357780 ) shareholders over the last week. Our...Reported Earnings • Mar 22Full year 2023 earnings released: EPS: ₩16,832 (vs ₩20,967 in FY 2022)Full year 2023 results: EPS: ₩16,832 (down from ₩20,967 in FY 2022). Revenue: ₩844.0b (down 23% from FY 2022). Net income: ₩130.4b (down 20% from FY 2022). Profit margin: 15% (in line with FY 2022). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 1% per year.Reported Earnings • Mar 26Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: ₩20,967 (up from ₩19,124 in FY 2021). Revenue: ₩1.09t (up 6.5% from FY 2021). Net income: ₩162.8b (up 9.6% from FY 2021). Profit margin: 15% (in line with FY 2021). Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) also missed analyst estimates by 11%. Revenue is forecast to grow 6.4% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in South Korea.すべての更新を表示Recent updatesBuy Or Sell Opportunity • May 20Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.8% to ₩392,000. The fair value is estimated to be ₩494,529, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.7% over the last 3 years. Earnings per share has declined by 24%. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 32% per annum over the same time period.Price Target Changed • May 05Price target increased by 11% to ₩428,846Up from ₩385,833, the current price target is an average from 13 analysts. New target price is 6.5% below last closing price of ₩458,500. Stock is up 158% over the past year. The company is forecast to post earnings per share of ₩20,528 for next year compared to ₩10,285 last year.Buy Or Sell Opportunity • Apr 30Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.2% to ₩458,000. The fair value is estimated to be ₩573,521, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.7% over the last 3 years. Earnings per share has declined by 24%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 32% per annum over the same time period.Reported Earnings • Mar 21Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: ₩10,285 (down from ₩15,296 in FY 2024). Revenue: ₩923.4b (up 7.0% from FY 2024). Net income: ₩79.1b (down 33% from FY 2024). Profit margin: 8.6% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 22%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Mar 11Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩442,000, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 106% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩419,479 per share.お知らせ • Mar 11Soulbrain Co., Ltd., Annual General Meeting, Mar 24, 2026Soulbrain Co., Ltd., Annual General Meeting, Mar 24, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 52, geumto-ro, sujeong-gu, gyeonggi-do, seongnam South KoreaPrice Target Changed • Mar 02Price target increased by 8.9% to ₩365,571Up from ₩335,667, the current price target is an average from 14 analysts. New target price is 18% below last closing price of ₩445,500. Stock is up 140% over the past year. The company is forecast to post earnings per share of ₩13,194 for next year compared to ₩15,296 last year.Valuation Update With 7 Day Price Move • Feb 06Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩407,000, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 75% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩490,528 per share.Declared Dividend • Feb 06Dividend increased to ₩2,350Dividend of ₩2,350 is 2.2% higher than last year. Ex-date: 30th March 2026 Payment date: 1st January 1970 Dividend yield will be 0.6%, which is lower than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (26% earnings payout ratio) but not covered by cash flows (118% cash payout ratio). The dividend has increased by an average of 3.8% per year over the past 5 years and payments have been stable during that time. EPS is expected to grow by 91% over the next 2 years, which should provide support to the dividend and adequate earnings cover.分析記事 • Feb 05Soulbrain (KOSDAQ:357780) Will Be Hoping To Turn Its Returns On Capital AroundThere are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...お知らせ • Feb 05Soulbrain Co., Ltd. announces Annual dividendSoulbrain Co., Ltd. announced Annual dividend of KRW 2350.0000 per share, ex-date on March 30, 2026 and record date on March 31, 2026.Price Target Changed • Feb 02Price target increased by 7.3% to ₩329,333Up from ₩307,063, the current price target is an average from 15 analysts. New target price is 21% below last closing price of ₩419,500. Stock is up 158% over the past year. The company is forecast to post earnings per share of ₩13,194 for next year compared to ₩15,296 last year.New Risk • Jan 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.5% net profit margin).Valuation Update With 7 Day Price Move • Jan 21Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩339,500, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 47% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩623,091 per share.分析記事 • Jan 08Market Participants Recognise Soulbrain Co., Ltd.'s (KOSDAQ:357780) EarningsWith a price-to-earnings (or "P/E") ratio of 33.7x Soulbrain Co., Ltd. ( KOSDAQ:357780 ) may be sending very bearish...Valuation Update With 7 Day Price Move • Nov 24Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩229,500, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 11% over the past three years.Major Estimate Revision • Nov 15Consensus EPS estimates increase by 14%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from ₩14,296 to ₩16,301. Revenue forecast steady at ₩922.7m. Net income forecast to grow 92% next year vs 49% growth forecast for Chemicals industry in South Korea. Consensus price target broadly unchanged at ₩289,643. Share price rose 3.5% to ₩268,000 over the past week.分析記事 • Nov 07What Is Soulbrain Co., Ltd.'s (KOSDAQ:357780) Share Price Doing?Soulbrain Co., Ltd. ( KOSDAQ:357780 ), is not the largest company out there, but it led the KOSDAQ gainers with a...分析記事 • Oct 22Soulbrain's (KOSDAQ:357780) Returns On Capital Not Reflecting Well On The BusinessIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...分析記事 • Sep 19Soulbrain Co., Ltd. (KOSDAQ:357780) Stocks Shoot Up 26% But Its P/E Still Looks ReasonableDespite an already strong run, Soulbrain Co., Ltd. ( KOSDAQ:357780 ) shares have been powering on, with a gain of 26...Valuation Update With 7 Day Price Move • Sep 12Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩242,000, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 22% over the past three years.分析記事 • Sep 07These 4 Measures Indicate That Soulbrain (KOSDAQ:357780) Is Using Debt Reasonably WellWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...New Risk • Aug 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Large one-off items impacting financial results.Major Estimate Revision • Aug 19Consensus EPS estimates fall by 13%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from ₩18,980 to ₩16,480 per share. Revenue forecast steady at ₩938.7m. Net income forecast to grow 35% next year vs 35% growth forecast for Chemicals industry in South Korea. Consensus price target broadly unchanged at ₩253,308. Share price fell 2.3% to ₩229,000 over the past week.Valuation Update With 7 Day Price Move • Jul 30Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩248,500, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 9.7% over the past three years.Valuation Update With 7 Day Price Move • Jul 16Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩211,500, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 3.3% over the past three years.分析記事 • Jul 12Soulbrain Co., Ltd.'s (KOSDAQ:357780) P/E Still Appears To Be ReasonableWith a median price-to-earnings (or "P/E") ratio of close to 14x in Korea, you could be forgiven for feeling...分析記事 • May 14Is There An Opportunity With Soulbrain Co., Ltd.'s (KOSDAQ:357780) 30% Undervaluation?Key Insights Soulbrain's estimated fair value is ₩265,300 based on 2 Stage Free Cash Flow to Equity Soulbrain's...お知らせ • Apr 16Soulbrain Co., Ltd. (KOSDAQ:A357780) announces an Equity Buyback for 86,009 shares, for KRW 15,000 million.Soulbrain Co., Ltd. (KOSDAQ:A357780) announces a share repurchase program. Under the program, the company will repurchase up to 86,009 shares for KRW 15,000 million worth of its shares pursuant to a trust agreement with NH Investment & Securities Co., Ltd. The shares will be repurchased at a price of KRW 174,400 per share. The purpose behind the program is to stabilize the stock price and to enhance shareholder value. The program will continue until October 14, 2025. As of Aril 14, 2025, the company had 22,994 common shares within dividend capacity and had 12,430 shares in treasury through other acquisitions.分析記事 • Apr 15Why Soulbrain Co., Ltd. (KOSDAQ:357780) Could Be Worth WatchingSoulbrain Co., Ltd. ( KOSDAQ:357780 ), might not be a large cap stock, but it saw a double-digit share price rise of...Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩161,200, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 8x in the Chemicals industry in South Korea. Total loss to shareholders of 31% over the past three years.分析記事 • Mar 24There May Be Some Bright Spots In Soulbrain's (KOSDAQ:357780) EarningsSoft earnings didn't appear to concern Soulbrain Co., Ltd.'s ( KOSDAQ:357780 ) shareholders over the last week. Our...Upcoming Dividend • Mar 21Upcoming dividend of ₩2,300 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 21 April 2025. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.7%).Major Estimate Revision • Mar 19Consensus EPS estimates fall by 11%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from ₩20,044 to ₩17,886 per share. Revenue forecast steady at ₩901.4m. Net income forecast to grow 9.4% next year vs 26% growth forecast for Chemicals industry in South Korea. Consensus price target broadly unchanged at ₩257,385. Share price was steady at ₩204,500 over the past week.お知らせ • Mar 11Soulbrain Co., Ltd., Annual General Meeting, Mar 25, 2025Soulbrain Co., Ltd., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 34-12, gongdan-gil, chungcheongnam-do, gongju South Korea分析記事 • Feb 21Soulbrain (KOSDAQ:357780) Might Be Having Difficulty Using Its Capital EffectivelyIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Valuation Update With 7 Day Price Move • Feb 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩188,100, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 8x in the Chemicals industry in South Korea. Total loss to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩331,465 per share.分析記事 • Jan 09Is There An Opportunity With Soulbrain Co., Ltd.'s (KOSDAQ:357780) 49% Undervaluation?Key Insights The projected fair value for Soulbrain is ₩351,381 based on 2 Stage Free Cash Flow to Equity Soulbrain is...Upcoming Dividend • Dec 20Upcoming dividend of ₩2,000 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 21 April 2025. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (2.2%).Board Change • Dec 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.分析記事 • Dec 02Unpleasant Surprises Could Be In Store For Soulbrain Co., Ltd.'s (KOSDAQ:357780) SharesWith a median price-to-earnings (or "P/E") ratio of close to 11x in Korea, you could be forgiven for feeling...Price Target Changed • Nov 16Price target decreased by 13% to ₩317,692Down from ₩363,167, the current price target is an average from 13 analysts. New target price is 66% above last closing price of ₩191,300. Stock is down 29% over the past year. The company is forecast to post earnings per share of ₩20,134 for next year compared to ₩16,832 last year.分析記事 • Nov 07At ₩204,500, Is Soulbrain Co., Ltd. (KOSDAQ:357780) Worth Looking At Closely?While Soulbrain Co., Ltd. ( KOSDAQ:357780 ) might not have the largest market cap around , it saw significant share...分析記事 • Oct 09Capital Allocation Trends At Soulbrain (KOSDAQ:357780) Aren't IdealIf you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...分析記事 • Jul 14At ₩288,000, Is Soulbrain Co., Ltd. (KOSDAQ:357780) Worth Looking At Closely?Soulbrain Co., Ltd. ( KOSDAQ:357780 ), is not the largest company out there, but it received a lot of attention from a...分析記事 • Jun 18Soulbrain (KOSDAQ:357780) Will Want To Turn Around Its Return TrendsWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...分析記事 • May 02There's Reason For Concern Over Soulbrain Co., Ltd.'s (KOSDAQ:357780) PriceWith a price-to-earnings (or "P/E") ratio of 17.9x Soulbrain Co., Ltd. ( KOSDAQ:357780 ) may be sending bearish signals...分析記事 • Apr 10Is It Time To Consider Buying Soulbrain Co., Ltd. (KOSDAQ:357780)?Soulbrain Co., Ltd. ( KOSDAQ:357780 ), might not be a large cap stock, but it saw a double-digit share price rise of...Reported Earnings • Mar 22Full year 2023 earnings released: EPS: ₩16,832 (vs ₩20,967 in FY 2022)Full year 2023 results: EPS: ₩16,832 (down from ₩20,967 in FY 2022). Revenue: ₩844.0b (down 23% from FY 2022). Net income: ₩130.4b (down 20% from FY 2022). Profit margin: 15% (in line with FY 2022). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 1% per year.分析記事 • Mar 20Estimating The Fair Value Of Soulbrain Co., Ltd. (KOSDAQ:357780)Key Insights Soulbrain's estimated fair value is ₩264,305 based on 2 Stage Free Cash Flow to Equity Current share price...分析記事 • Feb 27Some Investors May Be Worried About Soulbrain's (KOSDAQ:357780) Returns On CapitalIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...Upcoming Dividend • Dec 20Upcoming dividend of ₩2,000 per share at 0.7% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 22 April 2024. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.8%).Buying Opportunity • Dec 07Now 20% undervaluedOver the last 90 days, the stock is up 31%. The fair value is estimated to be ₩370,680, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 28% in 2 years. Earnings is forecast to grow by 35% in the next 2 years.Major Estimate Revision • Nov 15Consensus EPS estimates increase by 11%, revenue downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from ₩892.2m to ₩832.2m. EPS estimate rose from ₩16,585 to ₩18,348. Net income forecast to shrink 0.9% next year vs 46% growth forecast for Chemicals industry in South Korea . Consensus price target broadly unchanged at ₩307,143. Share price rose 11% to ₩270,500 over the past week.Valuation Update With 7 Day Price Move • Jul 17Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩275,500, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 24% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩280,170 per share.Reported Earnings • Mar 26Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: ₩20,967 (up from ₩19,124 in FY 2021). Revenue: ₩1.09t (up 6.5% from FY 2021). Net income: ₩162.8b (up 9.6% from FY 2021). Profit margin: 15% (in line with FY 2021). Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) also missed analyst estimates by 11%. Revenue is forecast to grow 6.4% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in South Korea.Major Estimate Revision • Mar 22Consensus revenue estimates fall by 10%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩1.17b to ₩1.05b. EPS estimate fell from ₩22,849 to ₩21,841 per share. Net income forecast to shrink 4.3% next year vs 30% growth forecast for Chemicals industry in South Korea . Consensus price target broadly unchanged at ₩291,222. Share price fell 3.9% to ₩210,000 over the past week.Upcoming Dividend • Dec 21Upcoming dividend of ₩1,950 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. Payout ratio is a comfortable 8.5% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (2.4%).お知らせ • Sep 30Soulbrain Co., Ltd. (KOSDAQ:A357780) announces an Equity Buyback for KRW 5,000 million worth of its shares.Soulbrain Co., Ltd. (KOSDAQ:A357780) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a trust agreement with Mirae Asset Securities Co., Ltd. The purpose behind the program is to stabilize the stock price and to enhance shareholder value. The program will continue until March 29, 2023. As of September 28, 2022, the company had no common shares within dividend capacity and had 12,430 shares in treasury through other acquisitions.Buying Opportunity • Apr 06Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 9.9%. The fair value is estimated to be ₩296,525, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.9% over the last year. Earnings per share has grown by 17%. Revenue is forecast to grow by 28% in 2 years. Earnings is forecast to grow by 34% in the next 2 years.Buying Opportunity • Mar 07Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 24%. The fair value is estimated to be ₩276,943, however this is not to be taken as a buy recommendation but rather should be used as a guide only.Upcoming Dividend • Dec 22Upcoming dividend of ₩1,950 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. Payout ratio is a comfortable 24% but the company is not cash flow positive. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (1.4%).Price Target Changed • Dec 08Price target decreased to ₩356,875Down from ₩388,571, the current price target is an average from 8 analysts. New target price is 26% above last closing price of ₩282,500. Stock is up 14% over the past year. The company is forecast to post earnings per share of ₩19,614 for next year compared to ₩16,288 last year.Valuation Update With 7 Day Price Move • Nov 24Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩273,800, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 9.1% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩261,923 per share.Price Target Changed • Nov 19Price target decreased to ₩359,286Down from ₩388,571, the current price target is an average from 7 analysts. New target price is 45% above last closing price of ₩248,100. Stock is up 0.7% over the past year. The company is forecast to post earnings per share of ₩19,824 for next year compared to ₩16,288 last year.Is New 90 Day High Low • Feb 17New 90-day high: ₩313,600The company is up 31% from its price of ₩240,000 on 19 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 29% over the same period.Is New 90 Day High Low • Jan 26New 90-day high: ₩300,000The company is up 36% from its price of ₩219,800 on 28 October 2020. The South Korean market is also up 36% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Chemicals industry, which is up 43% over the same period.Is New 90 Day High Low • Jan 04New 90-day high: ₩291,400The company is up 30% from its price of ₩224,000 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 22% over the same period.Is New 90 Day High Low • Dec 17New 90-day high: ₩273,800The company is up 17% from its price of ₩233,100 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 20% over the same period.Is New 90 Day High Low • Nov 23New 90-day high: ₩255,900The company is up 10.0% from its price of ₩232,000 on 26 August 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 13% over the same period.収支内訳Soulbrain の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史KOSDAQ:A357780 収益、費用、利益 ( )KRW Millions日付収益収益G+A経費研究開発費31 Dec 25923,38279,05855,59633,81630 Sep 25895,86067,34655,22033,20730 Jun 25874,66270,96155,33431,12331 Mar 25862,117103,59050,27729,43431 Dec 24863,356118,43749,11126,58230 Sep 24841,876143,18438,20723,92030 Jun 24809,344142,25133,30923,32131 Mar 24811,748130,93931,71722,81131 Dec 23844,029130,36330,98522,84130 Sep 23909,348126,09850,26924,02030 Jun 23998,158144,71360,33324,06231 Mar 231,052,268160,93064,27023,23031 Dec 221,090,867162,79467,77823,95230 Sep 221,095,909178,97958,99822,58230 Jun 221,095,628173,03852,86221,49731 Mar 221,066,326154,28848,41421,36731 Dec 211,023,913148,51743,88820,60531 Dec 20940,135126,53442,54221,748質の高い収益: A357780は 高品質の収益 を持っています。利益率の向上: A357780の現在の純利益率 (8.6%)は、昨年(13.7%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: A357780の収益は過去 5 年間で年間13.1%減少しました。成長の加速: A357780は過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: A357780は過去 1 年間で収益成長率がマイナス ( -33.2% ) となったため、 Chemicals業界平均 ( -3.4% ) と比較することが困難です。株主資本利益率高いROE: A357780の 自己資本利益率 ( 7.6% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 02:39終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Soulbrain Co., Ltd. 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。22 アナリスト機関Dong-je WooBofA Global ResearchYonghwan LeeCGS InternationalJosh YangCitigroup Inc19 その他のアナリストを表示
Reported Earnings • Mar 21Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: ₩10,285 (down from ₩15,296 in FY 2024). Revenue: ₩923.4b (up 7.0% from FY 2024). Net income: ₩79.1b (down 33% from FY 2024). Profit margin: 8.6% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 22%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.
分析記事 • Mar 24There May Be Some Bright Spots In Soulbrain's (KOSDAQ:357780) EarningsSoft earnings didn't appear to concern Soulbrain Co., Ltd.'s ( KOSDAQ:357780 ) shareholders over the last week. Our...
Reported Earnings • Mar 22Full year 2023 earnings released: EPS: ₩16,832 (vs ₩20,967 in FY 2022)Full year 2023 results: EPS: ₩16,832 (down from ₩20,967 in FY 2022). Revenue: ₩844.0b (down 23% from FY 2022). Net income: ₩130.4b (down 20% from FY 2022). Profit margin: 15% (in line with FY 2022). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 1% per year.
Reported Earnings • Mar 26Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: ₩20,967 (up from ₩19,124 in FY 2021). Revenue: ₩1.09t (up 6.5% from FY 2021). Net income: ₩162.8b (up 9.6% from FY 2021). Profit margin: 15% (in line with FY 2021). Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) also missed analyst estimates by 11%. Revenue is forecast to grow 6.4% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in South Korea.
Buy Or Sell Opportunity • May 20Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.8% to ₩392,000. The fair value is estimated to be ₩494,529, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.7% over the last 3 years. Earnings per share has declined by 24%. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 32% per annum over the same time period.
Price Target Changed • May 05Price target increased by 11% to ₩428,846Up from ₩385,833, the current price target is an average from 13 analysts. New target price is 6.5% below last closing price of ₩458,500. Stock is up 158% over the past year. The company is forecast to post earnings per share of ₩20,528 for next year compared to ₩10,285 last year.
Buy Or Sell Opportunity • Apr 30Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.2% to ₩458,000. The fair value is estimated to be ₩573,521, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.7% over the last 3 years. Earnings per share has declined by 24%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 32% per annum over the same time period.
Reported Earnings • Mar 21Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: ₩10,285 (down from ₩15,296 in FY 2024). Revenue: ₩923.4b (up 7.0% from FY 2024). Net income: ₩79.1b (down 33% from FY 2024). Profit margin: 8.6% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 22%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Mar 11Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩442,000, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 106% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩419,479 per share.
お知らせ • Mar 11Soulbrain Co., Ltd., Annual General Meeting, Mar 24, 2026Soulbrain Co., Ltd., Annual General Meeting, Mar 24, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 52, geumto-ro, sujeong-gu, gyeonggi-do, seongnam South Korea
Price Target Changed • Mar 02Price target increased by 8.9% to ₩365,571Up from ₩335,667, the current price target is an average from 14 analysts. New target price is 18% below last closing price of ₩445,500. Stock is up 140% over the past year. The company is forecast to post earnings per share of ₩13,194 for next year compared to ₩15,296 last year.
Valuation Update With 7 Day Price Move • Feb 06Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩407,000, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 75% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩490,528 per share.
Declared Dividend • Feb 06Dividend increased to ₩2,350Dividend of ₩2,350 is 2.2% higher than last year. Ex-date: 30th March 2026 Payment date: 1st January 1970 Dividend yield will be 0.6%, which is lower than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (26% earnings payout ratio) but not covered by cash flows (118% cash payout ratio). The dividend has increased by an average of 3.8% per year over the past 5 years and payments have been stable during that time. EPS is expected to grow by 91% over the next 2 years, which should provide support to the dividend and adequate earnings cover.
分析記事 • Feb 05Soulbrain (KOSDAQ:357780) Will Be Hoping To Turn Its Returns On Capital AroundThere are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...
お知らせ • Feb 05Soulbrain Co., Ltd. announces Annual dividendSoulbrain Co., Ltd. announced Annual dividend of KRW 2350.0000 per share, ex-date on March 30, 2026 and record date on March 31, 2026.
Price Target Changed • Feb 02Price target increased by 7.3% to ₩329,333Up from ₩307,063, the current price target is an average from 15 analysts. New target price is 21% below last closing price of ₩419,500. Stock is up 158% over the past year. The company is forecast to post earnings per share of ₩13,194 for next year compared to ₩15,296 last year.
New Risk • Jan 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.5% net profit margin).
Valuation Update With 7 Day Price Move • Jan 21Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩339,500, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 47% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩623,091 per share.
分析記事 • Jan 08Market Participants Recognise Soulbrain Co., Ltd.'s (KOSDAQ:357780) EarningsWith a price-to-earnings (or "P/E") ratio of 33.7x Soulbrain Co., Ltd. ( KOSDAQ:357780 ) may be sending very bearish...
Valuation Update With 7 Day Price Move • Nov 24Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩229,500, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 11% over the past three years.
Major Estimate Revision • Nov 15Consensus EPS estimates increase by 14%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from ₩14,296 to ₩16,301. Revenue forecast steady at ₩922.7m. Net income forecast to grow 92% next year vs 49% growth forecast for Chemicals industry in South Korea. Consensus price target broadly unchanged at ₩289,643. Share price rose 3.5% to ₩268,000 over the past week.
分析記事 • Nov 07What Is Soulbrain Co., Ltd.'s (KOSDAQ:357780) Share Price Doing?Soulbrain Co., Ltd. ( KOSDAQ:357780 ), is not the largest company out there, but it led the KOSDAQ gainers with a...
分析記事 • Oct 22Soulbrain's (KOSDAQ:357780) Returns On Capital Not Reflecting Well On The BusinessIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...
分析記事 • Sep 19Soulbrain Co., Ltd. (KOSDAQ:357780) Stocks Shoot Up 26% But Its P/E Still Looks ReasonableDespite an already strong run, Soulbrain Co., Ltd. ( KOSDAQ:357780 ) shares have been powering on, with a gain of 26...
Valuation Update With 7 Day Price Move • Sep 12Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩242,000, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 22% over the past three years.
分析記事 • Sep 07These 4 Measures Indicate That Soulbrain (KOSDAQ:357780) Is Using Debt Reasonably WellWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
New Risk • Aug 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Large one-off items impacting financial results.
Major Estimate Revision • Aug 19Consensus EPS estimates fall by 13%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from ₩18,980 to ₩16,480 per share. Revenue forecast steady at ₩938.7m. Net income forecast to grow 35% next year vs 35% growth forecast for Chemicals industry in South Korea. Consensus price target broadly unchanged at ₩253,308. Share price fell 2.3% to ₩229,000 over the past week.
Valuation Update With 7 Day Price Move • Jul 30Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩248,500, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 9.7% over the past three years.
Valuation Update With 7 Day Price Move • Jul 16Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩211,500, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 3.3% over the past three years.
分析記事 • Jul 12Soulbrain Co., Ltd.'s (KOSDAQ:357780) P/E Still Appears To Be ReasonableWith a median price-to-earnings (or "P/E") ratio of close to 14x in Korea, you could be forgiven for feeling...
分析記事 • May 14Is There An Opportunity With Soulbrain Co., Ltd.'s (KOSDAQ:357780) 30% Undervaluation?Key Insights Soulbrain's estimated fair value is ₩265,300 based on 2 Stage Free Cash Flow to Equity Soulbrain's...
お知らせ • Apr 16Soulbrain Co., Ltd. (KOSDAQ:A357780) announces an Equity Buyback for 86,009 shares, for KRW 15,000 million.Soulbrain Co., Ltd. (KOSDAQ:A357780) announces a share repurchase program. Under the program, the company will repurchase up to 86,009 shares for KRW 15,000 million worth of its shares pursuant to a trust agreement with NH Investment & Securities Co., Ltd. The shares will be repurchased at a price of KRW 174,400 per share. The purpose behind the program is to stabilize the stock price and to enhance shareholder value. The program will continue until October 14, 2025. As of Aril 14, 2025, the company had 22,994 common shares within dividend capacity and had 12,430 shares in treasury through other acquisitions.
分析記事 • Apr 15Why Soulbrain Co., Ltd. (KOSDAQ:357780) Could Be Worth WatchingSoulbrain Co., Ltd. ( KOSDAQ:357780 ), might not be a large cap stock, but it saw a double-digit share price rise of...
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩161,200, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 8x in the Chemicals industry in South Korea. Total loss to shareholders of 31% over the past three years.
分析記事 • Mar 24There May Be Some Bright Spots In Soulbrain's (KOSDAQ:357780) EarningsSoft earnings didn't appear to concern Soulbrain Co., Ltd.'s ( KOSDAQ:357780 ) shareholders over the last week. Our...
Upcoming Dividend • Mar 21Upcoming dividend of ₩2,300 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 21 April 2025. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.7%).
Major Estimate Revision • Mar 19Consensus EPS estimates fall by 11%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from ₩20,044 to ₩17,886 per share. Revenue forecast steady at ₩901.4m. Net income forecast to grow 9.4% next year vs 26% growth forecast for Chemicals industry in South Korea. Consensus price target broadly unchanged at ₩257,385. Share price was steady at ₩204,500 over the past week.
お知らせ • Mar 11Soulbrain Co., Ltd., Annual General Meeting, Mar 25, 2025Soulbrain Co., Ltd., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 34-12, gongdan-gil, chungcheongnam-do, gongju South Korea
分析記事 • Feb 21Soulbrain (KOSDAQ:357780) Might Be Having Difficulty Using Its Capital EffectivelyIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Valuation Update With 7 Day Price Move • Feb 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩188,100, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 8x in the Chemicals industry in South Korea. Total loss to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩331,465 per share.
分析記事 • Jan 09Is There An Opportunity With Soulbrain Co., Ltd.'s (KOSDAQ:357780) 49% Undervaluation?Key Insights The projected fair value for Soulbrain is ₩351,381 based on 2 Stage Free Cash Flow to Equity Soulbrain is...
Upcoming Dividend • Dec 20Upcoming dividend of ₩2,000 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 21 April 2025. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (2.2%).
Board Change • Dec 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
分析記事 • Dec 02Unpleasant Surprises Could Be In Store For Soulbrain Co., Ltd.'s (KOSDAQ:357780) SharesWith a median price-to-earnings (or "P/E") ratio of close to 11x in Korea, you could be forgiven for feeling...
Price Target Changed • Nov 16Price target decreased by 13% to ₩317,692Down from ₩363,167, the current price target is an average from 13 analysts. New target price is 66% above last closing price of ₩191,300. Stock is down 29% over the past year. The company is forecast to post earnings per share of ₩20,134 for next year compared to ₩16,832 last year.
分析記事 • Nov 07At ₩204,500, Is Soulbrain Co., Ltd. (KOSDAQ:357780) Worth Looking At Closely?While Soulbrain Co., Ltd. ( KOSDAQ:357780 ) might not have the largest market cap around , it saw significant share...
分析記事 • Oct 09Capital Allocation Trends At Soulbrain (KOSDAQ:357780) Aren't IdealIf you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...
分析記事 • Jul 14At ₩288,000, Is Soulbrain Co., Ltd. (KOSDAQ:357780) Worth Looking At Closely?Soulbrain Co., Ltd. ( KOSDAQ:357780 ), is not the largest company out there, but it received a lot of attention from a...
分析記事 • Jun 18Soulbrain (KOSDAQ:357780) Will Want To Turn Around Its Return TrendsWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...
分析記事 • May 02There's Reason For Concern Over Soulbrain Co., Ltd.'s (KOSDAQ:357780) PriceWith a price-to-earnings (or "P/E") ratio of 17.9x Soulbrain Co., Ltd. ( KOSDAQ:357780 ) may be sending bearish signals...
分析記事 • Apr 10Is It Time To Consider Buying Soulbrain Co., Ltd. (KOSDAQ:357780)?Soulbrain Co., Ltd. ( KOSDAQ:357780 ), might not be a large cap stock, but it saw a double-digit share price rise of...
Reported Earnings • Mar 22Full year 2023 earnings released: EPS: ₩16,832 (vs ₩20,967 in FY 2022)Full year 2023 results: EPS: ₩16,832 (down from ₩20,967 in FY 2022). Revenue: ₩844.0b (down 23% from FY 2022). Net income: ₩130.4b (down 20% from FY 2022). Profit margin: 15% (in line with FY 2022). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 1% per year.
分析記事 • Mar 20Estimating The Fair Value Of Soulbrain Co., Ltd. (KOSDAQ:357780)Key Insights Soulbrain's estimated fair value is ₩264,305 based on 2 Stage Free Cash Flow to Equity Current share price...
分析記事 • Feb 27Some Investors May Be Worried About Soulbrain's (KOSDAQ:357780) Returns On CapitalIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...
Upcoming Dividend • Dec 20Upcoming dividend of ₩2,000 per share at 0.7% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 22 April 2024. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.8%).
Buying Opportunity • Dec 07Now 20% undervaluedOver the last 90 days, the stock is up 31%. The fair value is estimated to be ₩370,680, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 28% in 2 years. Earnings is forecast to grow by 35% in the next 2 years.
Major Estimate Revision • Nov 15Consensus EPS estimates increase by 11%, revenue downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from ₩892.2m to ₩832.2m. EPS estimate rose from ₩16,585 to ₩18,348. Net income forecast to shrink 0.9% next year vs 46% growth forecast for Chemicals industry in South Korea . Consensus price target broadly unchanged at ₩307,143. Share price rose 11% to ₩270,500 over the past week.
Valuation Update With 7 Day Price Move • Jul 17Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩275,500, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 24% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩280,170 per share.
Reported Earnings • Mar 26Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: ₩20,967 (up from ₩19,124 in FY 2021). Revenue: ₩1.09t (up 6.5% from FY 2021). Net income: ₩162.8b (up 9.6% from FY 2021). Profit margin: 15% (in line with FY 2021). Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) also missed analyst estimates by 11%. Revenue is forecast to grow 6.4% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in South Korea.
Major Estimate Revision • Mar 22Consensus revenue estimates fall by 10%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩1.17b to ₩1.05b. EPS estimate fell from ₩22,849 to ₩21,841 per share. Net income forecast to shrink 4.3% next year vs 30% growth forecast for Chemicals industry in South Korea . Consensus price target broadly unchanged at ₩291,222. Share price fell 3.9% to ₩210,000 over the past week.
Upcoming Dividend • Dec 21Upcoming dividend of ₩1,950 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. Payout ratio is a comfortable 8.5% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (2.4%).
お知らせ • Sep 30Soulbrain Co., Ltd. (KOSDAQ:A357780) announces an Equity Buyback for KRW 5,000 million worth of its shares.Soulbrain Co., Ltd. (KOSDAQ:A357780) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a trust agreement with Mirae Asset Securities Co., Ltd. The purpose behind the program is to stabilize the stock price and to enhance shareholder value. The program will continue until March 29, 2023. As of September 28, 2022, the company had no common shares within dividend capacity and had 12,430 shares in treasury through other acquisitions.
Buying Opportunity • Apr 06Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 9.9%. The fair value is estimated to be ₩296,525, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.9% over the last year. Earnings per share has grown by 17%. Revenue is forecast to grow by 28% in 2 years. Earnings is forecast to grow by 34% in the next 2 years.
Buying Opportunity • Mar 07Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 24%. The fair value is estimated to be ₩276,943, however this is not to be taken as a buy recommendation but rather should be used as a guide only.
Upcoming Dividend • Dec 22Upcoming dividend of ₩1,950 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. Payout ratio is a comfortable 24% but the company is not cash flow positive. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (1.4%).
Price Target Changed • Dec 08Price target decreased to ₩356,875Down from ₩388,571, the current price target is an average from 8 analysts. New target price is 26% above last closing price of ₩282,500. Stock is up 14% over the past year. The company is forecast to post earnings per share of ₩19,614 for next year compared to ₩16,288 last year.
Valuation Update With 7 Day Price Move • Nov 24Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩273,800, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 9.1% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩261,923 per share.
Price Target Changed • Nov 19Price target decreased to ₩359,286Down from ₩388,571, the current price target is an average from 7 analysts. New target price is 45% above last closing price of ₩248,100. Stock is up 0.7% over the past year. The company is forecast to post earnings per share of ₩19,824 for next year compared to ₩16,288 last year.
Is New 90 Day High Low • Feb 17New 90-day high: ₩313,600The company is up 31% from its price of ₩240,000 on 19 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 29% over the same period.
Is New 90 Day High Low • Jan 26New 90-day high: ₩300,000The company is up 36% from its price of ₩219,800 on 28 October 2020. The South Korean market is also up 36% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Chemicals industry, which is up 43% over the same period.
Is New 90 Day High Low • Jan 04New 90-day high: ₩291,400The company is up 30% from its price of ₩224,000 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 22% over the same period.
Is New 90 Day High Low • Dec 17New 90-day high: ₩273,800The company is up 17% from its price of ₩233,100 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 20% over the same period.
Is New 90 Day High Low • Nov 23New 90-day high: ₩255,900The company is up 10.0% from its price of ₩232,000 on 26 August 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 13% over the same period.